International Summit on Psychedelic Therapies for Mental Illness

Speakers

• Dr Rick Doblin (USA)

  Executive Director of MAPS

  Dr Rick Doblin (USA)

  Executive Director of MAPS

  Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS).

  He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment.

  Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist.

  He founded MAPS in 1986, and currently resides in Boston with his wife, dog, and empty rooms from three children, one of whom is in college and two have graduated.

• Dr Gabor Maté CM (Canada)

  Physician and Author

  Dr Gabor Maté CM (Canada)

  Physician and Author

  Gabor Maté (pronunciation: GAH-bor MAH-tay) is a retired physician who, after 20 years of family practice and palliative care experience, worked for over a decade in Vancouver’s Downtown East Side with patients challenged by drug addiction and mental illness. The bestselling author of four books published in twenty-five languages, Gabor is an internationally renowned speaker highly sought after for his expertise on addiction, trauma, childhood development, and the relationship of stress and illness. His book on addiction received the Hubert Evans Prize for literary non-fiction. For his groundbreaking medical work and writing he has been awarded the Order of Canada, his country’s highest civilian distinction, and the Civic Merit Award from his hometown, Vancouver. His books include In the Realm of Hungry Ghosts: Close Encounters With Addiction; When the Body Says No; The Cost of Hidden Stress; Scattered Minds: The Origins and Healing of Attention Deficit Disorder; and (with Gordon Neufeld) Hold on to Your Kids: Why Parents Need to Matter More Than Peers. To learn more, join his enews list at www.drgabormate.com.

• Professor David Nutt (UK)

  Head of Neuropsychopharmacology at Imperial College London and Chief Research Officer at Awakn Life Sciences

  Professor David Nutt (UK)

  Head of Neuropsychopharmacology at Imperial College London and Chief Research Officer at Awakn Life Sciences

  BA, MB BChir, MRCP, MA, DM, MRCPsych, FRCPsych, FMedSci, FRCP, FSB.

  Renowned researcher, policy advisor and author, Professor David Nutt, is currently Head of Neuropsychopharmacology at Imperial College London.

  Under the leadership of Professor Nutt, the Psychedelic Research Group at Imperial College is one of the world’s foremost psychedelic research laboratories, publishing landmark research on psychedelic therapies and neuroimaging studies of the psychedelic state.

  Professor Nutt has also held many leadership positions in both UK and European academic, scientific and clinical organisations, including presidencies of: the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology.

  He was previously Chair of the UK Advisory Council on the Misuse of Drugs.

• Prof Roland Griffiths (USA)

  Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine

  Prof Roland Griffiths (USA)

  Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine

  Roland Griffiths, Ph.D., is Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine. His principal research focus in both clinical and pre-clinical laboratories has been on the behavioural and subjective effects of mood-altering drugs. His research has been largely supported by grants from the National Institute on Health and he is author of 380 journal articles and book chapters. He has been a consultant to the National Institutes of Health, to numerous pharmaceutical companies in the development of new psychotropic drugs, and as a member of the Expert Advisory Panel on Drug Dependence for the World Health Organization.

  He has conducted extensive research with sedative-hypnotics, caffeine, and novel mood-altering drugs. In 1999 he initiated a research program investigating the effects of the classic psychedelic psilocybin that includes studies in psychedelic naive and experienced volunteers, in beginning and long-term meditators, and in religious leaders.

  Studies have also have examined the effects of salvinorin A, dextromethorphan, and ketamine which produce altered states of consciousness having some similarities to psilocybin.  Therapeutic studies with psilocybin include treatment of psychological distress in cancer patients, treatment of cigarette smoking cessation, and psilocybin treatment of major depression. Drug interaction studies and brain imaging studies (fMRI and PET) are examining pharmacological and neural mechanisms of action. The Hopkins laboratory has also conducted a series of internet survey studies characterizing various psychedelic experiences including those associated with acute and enduring adverse effects, mystical-type effects, entity and God-encounter experiences, and alleged positive changes in mental health, including decreases in depression and anxiety, decreases in substance abuse, and reductions in death anxiety.

• Professor Robin Carhart-Harris (UK)

  Ralph Metzner Distinguished Professor, Weill Institute for Neurosciences and University of California San Francisco

  Professor Robin Carhart-Harris (UK)

  Ralph Metzner Distinguished Professor, Weill Institute for Neurosciences and University of California San Francisco

  Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University. At Imperial, he has run and overseen brain imaging studies involving LSD, psilocybin, MDMA and DMT, plus a clinical trial of psilocybin for treatment-resistant depression, and a current study comparing psilocybin with escitalopram for major depressive disorder. In 2019, he set-up the Centre for Psychedelic Research at Imperial and he also an honorary position with the University of Oxford. Two of his most influential works include the ‘Entropic Brain Hypothesis’ and ‘REBUS and the anarchic brain’.

• Francoise Bourzat (USA)

  Psychedelic Guide Trainer and Author

  Francoise Bourzat (USA)

  Psychedelic Guide Trainer and Author

  Francoise Bourzat is a counselor in the San Francisco Bay Area.

  She holds a master’s degree in Somatic Psychology and graduated from the Hakomi Institute.

  In collaboration with healers in the USA and in Mexico, she has practiced and guided ceremonies with sacred mushrooms for the last 35 years.

  She has been an adjunct faculty at CIIS in San Francisco,  she runs online courses and lectures in various institutions.

  She collaborates in an FDA approved research on psilocybin-assisted therapy for Covid related grief in Los Angeles and runs bereaved parents’ grief retreats in Jamaica in collaboration with American, Canadian and Jamaican physicians.

  She is the co-founder of the Center for Consciousness Medicine.

  She trains psychedelic guides internationally and is the author of the book entitled Consciousness Medicine, North Atlantic Books, Berkeley, CA.

• Johann Hari (UK)

  Journalist and best-selling Author

  Johann Hari (UK)

  Journalist and best-selling Author

  Johann Hari’s first book, Lost Connections: Why You’re Depressed and How to Find Hope, is being translated into 27 languages and has been praised by a broad range of people — from Elton John (who said it “will change your life”) to the British Journal of General Practice, who called it “one of the most important texts in recent years.” His second book, Chasing the Scream: The First and Last Days of the War on Drugs, has been translated into 15 languages and is currently being adapted into a major Hollywood film by Oscar-winning director Lee Daniels, and into a non-fiction documentary series.

  Hari graduated from Cambridge University with the highest degree grade, a Double First, in social and political sciences. He grew up in London, with a Swiss father who was a bus driver and a Scottish mother who worked in a shelter for victims of domestic violence. Today, he lives half the year in London, and he spends the other half of the year traveling to research his books.

  Hari has written over the past eight years for some of the world’s leading newspapers and magazines, including the New York Times, the Los Angeles Times, the Guardian, the Spectator, Le Monde Diplomatique, the Melbourne Age and Politico. He has also appeared on leading TV shows, including HBO’s Realtime With Bill Maher. He was twice named “National Newspaper Journalist of the Year” by Amnesty International. He has also been named “Cultural Commentator of the Year” and “Environmental Commentator of the Year” at the Comment Awards, and “Gay Journalist of the Year” at the Stonewall Awards. Read about what Johann is working on now.

• Dr Ben Sessa (UK)

  Chief Medical Officer at Awakn Life Sciences, Psychiatrist, Researcher and Writer

  Dr Ben Sessa (UK)

  Chief Medical Officer at Awakn Life Sciences, Psychiatrist, Researcher and Writer

  Dr Ben Sessa trained at UCL, London, graduating in Medicine in 1997.

  He works clinically as an adult and adolescent psychiatrist, and academically in Bristol and Imperial College London University, with an interest in the developmental trajectory from child maltreatment to adult mental health disorders.

  In the last ten years Ben has been a study doctor and a test subject administering and receiving legal doses of pure LSD, psilocybin, MDMA, DMT.

  He is currently conducting the world’s first clinical study using MDMA to treat addiction. Ben is the co-founder and past President of the UK’s premier psychedelic research conference, Breaking Convention.

  He has published dozens of peer reviewed papers on psychedelics and is the Author of several textbooks, including the influential book ‘The Psychedelic Renaissance‘.

• Dr Alberto Villoldo (USA)

  Founder the Four Winds Society, Director the Center for Energy Medicine (Chile)

  Dr Alberto Villoldo (USA)

  Founder the Four Winds Society, Director the Center for Energy Medicine (Chile)

  Medical anthropologist Alberto Villoldo Ph.D. has studied the shamanic healing practices of the Amazon and Andes for more than 25 years. In 1984 he founded the Four Winds Society, which offers extensive education in the philosophy and practice of energy medicine. In his mid-20s Villoldo was the youngest clinical professor at San Francisco State University, where he founded and directed the Biological Self-Regulation Lab to investigate how visualization, energy and psychosomatic medicine change the chemistry of the brain. He soon realized that the microscope was the wrong instrument to answer the questions he was asking. Other scientists were already studying the hardware, Villoldo wanted to learn to reprogram the system.

  Over the course of two decades with the shamans in the jungles and high mountains of the Andes, Alberto Villoldo discovered a set of sacred technologies that transform the body, heal the soul, and can change the way we live and die.

  He learned that we are more than flesh and bone – we are absolutely fashioned of Spirit and light, surrounded by a Luminous Energy Field whose source is located in infinity. This unending Luminous Energy Field exists in every cell of our bodies, acting as a matrix that maintains our physical and spiritual health and vibrancy … it is up to us to recognize and work with this gift to change the very nature of our living.

  Dr. Alberto Villoldo has written numerous international best-selling books including One Spirit Medicine.

• Professor Matthew Johnson (USA)

  Susan Hill Ward Professor of Psychedelics at Johns Hopkins University School of Medicine

  Professor Matthew Johnson (USA)

  Susan Hill Ward Professor of Psychedelics at Johns Hopkins University School of Medicine

  Matthew W. Johnson, Ph.D., is The Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research at Johns Hopkins University School of Medicine. Working with psychedelics since 2004, he is one of the world’s most widely published experts on psychedelics. He has published over 150 scientific papers, including psychedelic safety guidelines (2008) that helped to resurrect human psychedelic research, the first research on psychedelic treatment of tobacco addiction (2014), and studies of psilocybin in cancer-related distress (2016) and depression (2020). His psilocybin review recommended Schedule IV upon potential medical approval (2018). Matt also conducts behavioral economic research on the psychology of drug use, addiction, and sexual risk. He is a past President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association, and current President of the International Society for Research on Psychedelics. In 2021 Matt received as principal investigator the first grant awarded by the US government in 50 years for a treatment trial of a classic psychedelic (psilocybin for smoking cessation). He has been interviewed by Anderson Cooper on 60 Minutes, the New York Times, the Washington Post, the Wall Street Journal, the BBC, CNN, Fox Business News, NPR, and in Michael Pollan’s book How to Change Your Mind.

  Twitter: @Drug_Researcher

• Dr William Richards (USA)

  Psychologist in the Center for Psychedelic and Consciousness Research

  Dr William Richards (USA)

  Psychologist in the Center for Psychedelic and Consciousness Research

  William A. Richards (Bill),  a psychologist in the Center for Psychedelic and Consciousness Research at the Johns Hopkins School of Medicine, has been implementing research studies with psilocybin since 1999. His graduate degrees include M.Div. (Yale) , S.T.M.  (Andover-Newton) and  Ph.D. (Catholic University). He also studied with Abraham Maslow at Brandeis University and with Hanscarl Leuner at Georg-August University in Göttingen, Germany, where his involvement with psilocybin research originated in 1963. From 1967 to 1977, he implemented projects of psychotherapy research with  LSD, DPT, MDA and psilocybin at the Maryland Psychiatric Research Center, including protocols designed to investigate the promise of psychedelics in the treatment of alcoholism, depression,  narcotic addiction and the psychological distress associated with terminal cancer, and also their use in the training of religious and mental-health professionals. His book, Sacred Knowledge: Psychedelics and Religious Experiences has been released by Columbia University Press.

• Dr Lynn Marie Morski (USA)

  President of the Psychedelic Medicine Association

  Dr Lynn Marie Morski (USA)

  President of the Psychedelic Medicine Association

  Lynn Marie Morski, MD, JD, is the president of the Psychedelic Medicine Association, host of the Plant Medicine Podcast, founder of Plant Medicine.org, and the medical director for Way of Leaf.com.

  Dr. Morski received her medical degree from Saint Louis University School of Medicine, did a family medicine residency at Mayo Clinic, and completed a sports medicine fellowship at the University of Arizona. She received her law degree from Thomas Jefferson School of Law, is a current member of the California Bar, and a former adjunct professor of health law.

  Dr. Morski spent nine years as a physician at the Veterans Administration. Her biggest frustration during her years working for the federal government at the VA was that she was unable to discuss the benefits of psychedelic-assisted therapy she knew could help the veterans she was serving. After leaving the VA in 2019, she made it her mission to help educate physicians on the plant medicines and entheogens that could bring life-changing healing to their patients.

  In furtherance of this mission, she started the Plant Medicine Podcast and Plant Medicine.org in 2019. On the Plant Medicine Podcast, Dr. Morski interviews experts across all realms of psychedelic science on topics including scientific research, patient experiences with psychedelic therapies, benefits of psychedelic medicines, and the challenges faced in this emerging field.

  In 2020, and she and her team founded the Psychedelic Medicine Association to formally educate healthcare professionals on psychedelic medicines. Informing frontline healthcare providers is a crucial first step in getting these therapies to the patients who could benefit from them. In addition to clinician members, the Psychedelic Medicine Association also welcomes organizational members from across the psychedelic sphere who are working on other aspects necessary to ensure equitable access to these medicines for all patients. For more information, visit psychedelicmedicineassociation.org.

• Dr. Srinivas Rao (USA)

  MD, PhD, co-founder & Chief Scientific Officer, atai Life Sciences

  Dr. Srinivas Rao (USA)

  MD, PhD, co-founder & Chief Scientific Officer, atai Life Sciences

  Srinivas Rao is the Chief Scientific Officer at atai Life Sciences AG. Dr. Rao has over 19 years of professional experience in the pharmaceutical and biotechnology industries.

  Prior to atai, Dr. Rao has held the titles of Chief Scientific, Medical, or Executive Officer at companies ranging from venture backed startups to vertically-integrated, publicly traded pharmaceutical companies.

  Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. He received his Ph.D. in neurobiology from Yale Graduate School and his M.D. from Yale School of Medicine. He holds both a Bachelor of Science and Master of Science degree in Electrical Engineering from Yale College and Yale Graduate School, respectively.

• Wade Davis CM (Canada)

  Professor of Anthropology & BC Leadership Chair in Cultures and Ecosystems at Risk at the University of British Columbia

  Wade Davis CM (Canada)

  Professor of Anthropology & BC Leadership Chair in Cultures and Ecosystems at Risk at the University of British Columbia

  Wade Davis is a writer, photographer, and filmmaker whose work has taken him from the Amazon to Tibet, Africa to Australia, Polynesia to the Arctic. Explorer-in-Residence at the National Geographic Society from 2000 to 2013, he is currently Professor of Anthropology and the BC Leadership Chair in Cultures and Ecosystems at Risk at the University of British Columbia. Author of 22 books, including One River, The Wayfinders and Into the Silence, winner of the 2012 Samuel Johnson prize, the top nonfiction prize in the English language, he holds degrees in anthropology and biology and received his Ph.D. in ethnobotany, all from Harvard University.

  His many film credits include Light at the Edge of the World, an eight-hour documentary series written and produced for the NGS. Davis, one of 20 Honorary Members of the Explorers Club, is the recipient of 11 honorary degrees, as well as the 2009 Gold Medal from the Royal Canadian Geographical Society, the 2011 Explorers Medal, the 2012 David Fairchild Medal for botanical exploration, the 2015 Centennial Medal of Harvard University, the 2017 Roy Chapman Andrews Society’s Distinguished Explorer Award, the 2017 Sir Christopher Ondaatje Medal for Exploration, and the 2018 Mungo Park Medal from the Royal Scottish Geographical Society. In 2016, he was made a Member of the Order of Canada. In 2018 he became an Honorary Citizen of Colombia.

• Dr. Rami Batal (Canada)

  PharmD/PhD, Chief Executive Officer - Universal Ibogaine

  Dr. Rami Batal (Canada)

  PharmD/PhD, Chief Executive Officer - Universal Ibogaine

  Dr. Rami Batal is a seasoned biopharmaceutical industry executive and a healthcare professional who has a passion for, and expertise and experience in, neuropsychiatry and mental health/behavioral health illnesses, including substance use disorders.  Dr. Batal has occupied leadership and influencing roles in research and development, strategic marketing and business development at Antibe Therapeutics, Canopy Growth, Beckley-Canopy (now Beckly-Psytech), Purdue Canada, and Yumanity Therapeutics. Dr. Batal holds a doctorate in Experimental Medicine from McGill, and an MBA from Concordia. He is a Canada Board certified Pharmacist, and is licensed to practice.

• Kelsey Ramsden (Canada)

  Co-Founder, CEO + President MINDCURE

  Kelsey Ramsden (Canada)

  Co-Founder, CEO + President MINDCURE

  With over fifteen years founding, scaling, and operating innovative companies across Canada and the Caribbean, Kelsey Ramsden is globally recognized for building multiple multimillion-dollar businesses. She twice earned the honor of being named Canada’s Top Female Entrepreneur and serves on the Entrepreneurship Council for the University of Western Ontario. Kelsey is a renowned thought leader and published author and holds an MBA from the Richard Ivey School of Business at the University of Western Ontario.

  Accomplishments include founding construction firm Belvedere Place Development and residential project-management company Tallus Ridge Development in British Columbia – breaking barriers in traditionally male dominated fields.

  MINDCURE’S mission is to identify and develop products that ease suffering, increase productivity, and enhance mental health. It was born, in part, as a response to the mental health crisis and the need to find effective treatments in areas beyond psychiatry. These include digital therapeutics, neuro-supports, and psychedelics.

  Referring to MINDCURE as the Netflix of Mental Health, Ramsden cites that the company’s digital therapeutics platform iSTRYM has parallel qualities, constantly optimizing and customizing to provide predictive, personalized recommendations.

  “Our tech is more deliberate than others’ and at scale, I believe we will have the largest psychedelic repository of human experience data — which means we can shorten the time it takes to heal.”

  With a psychedelic Renaissance underway, Ramsden finds herself a pioneer on a frontier (again) – and with the most precious of commodities. “We have one mind,” she said. “It’s our greatest asset.”

• Dr Lyle Oberg (Canada)

  Co-Founder and CEO at MYND

  Dr Lyle Oberg (Canada)

  Co-Founder and CEO at MYND

  A physician by profession, Dr. Oberg possesses extensive senior leadership, finance and corporate governance experience. Elected to the Legislature and first appointed to the Government of Alberta Cabinet in 1997, serving in cabinet posts of Family & Social Services, Education, Advanced Education, Infrastructure, Transportation and Minister of Finance. Oberg left government in 2008 with one of the largest surpluses in Alberta history. Oberg later founded and became CEO of C2DNA, the first private DNA testing facility in Canada; then joined the Flowr Corporation as CEO. He was a member of the Ernst and Young Expert Panel reviewing Alberta Health Services $21.9 billion annual budget and was recently appointed by Order in Council to the Physician Compensation Advisory Committee. Dr. Oberg is a director of Yorkville Asset Management which was founded in 2010 has approximately $3 billion under management. He currently sits on the board of Centric Healthcare and Eyam Vaccines.

• Dr Jennifer Mitchell (USA)

  Professor in the Departments of Neurology and Psychiatry and Behavioral Sciences at UCSF

  Dr Jennifer Mitchell (USA)

  Professor in the Departments of Neurology and Psychiatry and Behavioral Sciences at UCSF

  Dr. Jennifer Mitchell is a Professor in the Departments of Neurology and Psychiatry and Behavioral Sciences at UCSF and the Deputy Associate Chief of Staff for Research and Development at the San Francisco VA. Dr. Mitchell’s translational neuroscience research rests at the intersection of psychology, behavioral pharmacology, and neuroanatomy and is primarily focused on identifying and developing novel therapeutics for affective disorders (drug and alcohol abuse, PTSD, stress, anxiety, depression, and impulsivity) and on understanding the neural mechanisms responsible for these disorders. Dr. Mitchell has extensive and diverse experience with human and animal pharmacology, hypothesis-driven neuroscience, human proof-of-concept studies, and clinical trials. For the past few years, her work has centered around the development of psychedelic medicines for a broad range of mental health conditions.

• Ronan Levy (Canada)

  Co-founder and the Executive Chairman of Field Trip Health

  Ronan Levy (Canada)

  Co-founder and the Executive Chairman of Field Trip Health

  Believing that you should never hesitate to trade your cow for a handful of magic beans, Ronan has built a career out of doing things that others say cannot be done. Ronan started his career as a securities lawyer at Blake, Cassels & Graydon LLP but left that after realizing he was much too creative for the profession of law. Since then, Ronan has helped launch business across a number of industries from gold, to cannabis, and, most recently, in psychedelics where he is a Co-founder and the Executive Chairman of Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF), a global leader in the development and delivery of psychedelic therapies. When not being thoroughly incorrigible, Ronan lives in Toronto with his wife and two children.

• Joseph Araujo (Canada)

  Co-Founder and Chief Scientific Officer of Mindset Pharma and the CEO and President of InterVivo Solutions

  Joseph Araujo (Canada)

  Co-Founder and Chief Scientific Officer of Mindset Pharma and the CEO and President of InterVivo Solutions

  Joseph is a co-founder and Chief Scientific Officer of Mindset Pharma and the CEO and President of InterVivo Solutions. Joseph is a behavioural pharmacologist with extensive experience in facilitating the discovery and development of novel CNS drugs. He has co-founded, held executive level positions and consulted for several life science  companies including CanCog Technologies, Vivocore, Karyopharm Therapeutics, NPM Pharma, Ketogen, and Epione Animal Health. Joseph did his graduate training in pharmacology at the University of Toronto and has done extensive research examining psychoactive drugs. He has over 35 publications in peer reviewed scientific journals and has spoken extensively at scientific meetings.

• Dr Reid Robison (USA)

  Psychiatrist, Researcher & Chief Medical Officer, Novamind

  Dr Reid Robison (USA)

  Psychiatrist, Researcher & Chief Medical Officer, Novamind

  Reid Robison, MD MBA, is a Psychiatrist, Researcher & Chief Medical Officer at Novamind. He has led over 100 clinical trials in neuropsychiatry and co-directed the molecular genetics laboratory at the University of Utah Department of Psychiatry. Reid is co-founder at Cedar Psychiatry, and serves as Medical Director of Center for Change, a top Eating Disorder treatment program. He was the coordinating investigator for the MAPS MDMA-assisted Psychotherapy study of Eating Disorders. He was one of the first clinicians to use k. off label for depression in Utah and obtained his first grant to study k. in 2011. He also led the Utah site for the pivotal IV k. study for treatment-resistant depression by Janssen, leading up to the company’s recent FDA-approval of Spravato (esketamine) via breakthrough therapy designation in 2019. Reid supervises & trains the k. -assisted psychotherapy practitioners at Cedar Psychiatry’s clinics across Utah, and to date has guided thousands of k. therapy journeys and, and hundreds of Spravato dosing sessions. As a social entrepreneur, Reid has built and sold a number of purpose-driven companies including Tute Genomics, a venture-backed personalized medicine startup that was acquired in 2016. Reid is adjunct faculty at the University of Utah, Brigham Young University, and Utah Valley University, has served on numerous non-profit boards. He founded the Polizzi Free Clinic, to bring mental health to Utah’s uninsured, and most recently co-founded SCPTR, a psychedelic therapy & research non-profit. He currently volunteers as medical support and a psychedelic therapist at Ayahuasca retreats abroad, and often provides medical safety consultations to shamans, therapists and researchers working in psychedelic medicine. Reid continues to share his vision for personalized medicine whenever he gets the chance as you can see in his TEDx talk entitled “The Genome Revolution Begins with You.”

• Dr Patrycja Slawuta (USA)

  Behavioural Scientist

  Dr Patrycja Slawuta (USA)

  Behavioural Scientist

  Patrycja Slawuta is a New York City based behavioral scientist. She completed her Masters Degree at the University of Warsaw where here research centered around moral emotions of guilt and shame. Her academic work has been presented at various scientific conferences and published in articles and books on social psychology. After a successful academic career, Patrycja founded SelfHackathon, a boutique consultancy that uses cutting edge scientific research for business innovation. With a network of 50+ scientists and domain experts, SelfHackathon helps high performing individuals, teams and companies hack, rewire and upgrade themselves. Her latest initiative is called PsychTech, the seamless fusion of psychology and technology to enhance and accelerate performance and results. As an expert on the complexity, nonlinearity and the messiness of the human nature, Patrycja lectures globally and works with some of the most exciting and disruptive businesses in the world.

• Hon Andrew Robb AO

  Former Minister for Trade, Investment and Tourism in Australia

  Hon Andrew Robb AO

  Former Minister for Trade, Investment and Tourism in Australia

  Until his recent retirement from politics, Andrew Robb was Australia’s Minister for Trade, Investment and Tourism.
  In this role Mr Robb negotiated Free Trade Agreements with South Korea, Japan and China, as well as the 12 country Trans Pacific Partnership (TPP) free trade agreement and the Comprehensive Strategic Partnership with Singapore.

  Mr Robb is currently Executive Chairman of The Robb Group (A corporate and investment advisory company), a Board Member of the Kidman cattle enterprise, Chair of Asialink and pharmacogenetics company, CNSDose, and strategic advisor to Seafarms Ltd as well as a range of national and international businesses.

  In 2003, Mr Robb was awarded the office of the Order of Australia (AO) for his service to agriculture, politics and the community. As well, Mr Robb is the author of “Black Dog Daze: Public Life, Private Demons” (Melbourne University Publishing).

  Mr Robb has qualifications in Agricultural Science and a first-class Honours Degree in Economics, and lives in Sydney with his wife Maureen and has three adult children Tom, Joe and Pip.

• Admiral Chris Barrie AC

  Former Head of the Australian Defence Force (1998-2002) and Strategic Leadership Consultant

  Admiral Chris Barrie AC

  Former Head of the Australian Defence Force (1998-2002) and Strategic Leadership Consultant

  Admiral Chris Barrie commanded all arms of the Defence Force as its Chief (CDF) from 1998 till 2002. After this, Chris worked on strategic leadership as a consultant, teacher and mentor, initially through Oxford University’s Strategic Leadership and Stimulus Forum Programs (2002-2011); and as Distinguished Visiting Professor he also taught an elective on Strategic Leadership to senior U.S. military officers at the National Defense University in Washington DC from 2004 till 2010.

  He is busy now as the founder and Chair of Fearless – PTSD (Australia New Zealand), whose subsidiary ‘FearLess Outreach’ is intended to assist an estimated 6 million people in the Australian and New Zealand communities, who live with post-traumatic stress. He is an outspoken commentator on Climate Change and Security using community advocacy to raise awareness of the potential costs of inaction. Chris is also the Australian member of the Global Military Advisory Council on Climate Change (GMACCC), and an adjunct member of the Planetary Security Initiative based in the Hague.

• Dr Michael Winlo

  Managing Director, Emyria

  Dr Michael Winlo

  Managing Director, Emyria

  Michael is Managing Director at Emyria, a data-driven, drug development and clinical services company focused on improving care of patients with unmet needs. Emyria leverages the clinical evidence created with patients to launch and register novel drug development and treatment programs with global regulators. Michael is also a Director at Linear Clinical Research – Perth’s only dedicated early phase cancer and clinical trial unit. Michael was previously CEO at Linear which, under his leadership, was the first site in Australia to complete a comprehensive digital transformation. Prior to Linear, Michael lived and worked in Silicon Valley leading the Health team at Palantir working with major healthcare institutions in the US and UK to solve complex data integration and analysis challenges. Michael is a medical doctor with an MBA from Stanford and holds several data analysis patents.

• John Skerritt

  Deputy Secretary, Health Products Regulation Group

  John Skerritt

  Deputy Secretary, Health Products Regulation Group

  Adjunct Professor John Skerritt joined the Australian Department of Health in 2012 as a Deputy Secretary. Apart from being part of the Executive team of Australia’s national Health Department, responsible for the Federal government’s $100 billion investment in health, aged care and sport he also has line responsibility for the Therapeutic Goods Administration and the Office of Drug Control. He was formerly a Deputy Secretary in the Victorian Government, Deputy CEO of a Commonwealth Statutory Authority in the Australian overseas aid program, senior research manager in CSIRO and in industry joint venture partnerships. From 2009-2012, he was Chair of the Board of a global technical non-government organisation, and was a board member for two further years. John is an Adjunct Full Professor in medicine, pharmacy and agriculture at three Universities, has a PhD and a University Medal from the University of Sydney, and is a graduate of the Senior Executive Programs of London Business School and of the International Institute for Management Development in Switzerland. He was elected a Fellow of the Academy of Technological Sciences and Engineering and a Fellow of the Institute of Public Administration of Australia (Vic).

• Arthur Christopoulos

  Professor of Analytical Pharmacology, a molecular Neuropsychopharmacologist, and Dean of the Faculty of Pharmacy & Pharmaceutical Sciences

  Arthur Christopoulos

  Professor of Analytical Pharmacology, a molecular Neuropsychopharmacologist, and Dean of the Faculty of Pharmacy & Pharmaceutical Sciences

  Arthur Christopoulos is Professor of Analytical Pharmacology, a molecular neuropsychopharmacologist, and Dean of the Faculty of Pharmacy & Pharmaceutical Sciences, Monash University Parkville (#1 Faculty in Australia; #2 in the world – Pharmacy & Pharmacology; QS World Rankings, 2021). Prior to his appointment as Dean, he was a Senior Principal Research Fellow of the NHMRC. His research focuses on novel paradigms of drug action at G protein-coupled receptors (GPCRs), the largest drug-target class for current medicines. His innovative research crosses academic and industry boundaries, incorporating computational and mathematical modelling, structural and chemical biology, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease. His research has been applied to fundamental and translational studies encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes and chronic pain, to name a few, and he has received substantial, long-term support from international and national competitive (e.g., NIH; NHMRC; ARC), charitable (e.g., Wellcome Trust) and commercial (e.g., Servier, GSK, Pfizer, Amgen, Eli Lilly) sources.

  Professor Christopoulos has published over 320 publications, including in leading journals such as Nature, Science, Cell, Nature Chemical Biology, PNAS and Nature Communications, and delivered over 180 invited presentations. He has served on the Editorial Board of 8 international journals, consults for numerous companies, (including most major pharma and many biotech) and is a Councillor of the International Union of Basic and Clinical Pharmacology (IUPHAR). He has also been the recipient of multiple awards, including the John J. Abel Award from the American Society for Pharmacology and Experimental Therapeutics, the Rand Medal from the Australian Society of Clinical and Experimental Pharmacologists and Toxicologists, the British Pharmacological Society (BPS) Gaddum Memorial Award, the IUPHAR Analytical Pharmacology Lecturer, the GSK Award for Research Excellence and a Doctor of Laws from the University of Athens. Since 2014-present, Clarivate Analytics have named him a Highly Cited Researcher (top 1% worldwide) in Pharmacology and Toxicology. In 2017, he was elected a Fellow of the Australian Academy of Health and Medical Sciences and of the BPS, and this year (2021) was elected a Fellow of the Australian Academy of Science for his seminal contributions to novel drug discovery.

• Dr Eli Kotler

  Psychiatrist and Director of Medicine at Malvern Private Hospital

  Dr Eli Kotler

  Psychiatrist and Director of Medicine at Malvern Private Hospital

  MBBS MPM FRANZCP Cert. Old Age Psych. AFRACMA

  Eli is a consultant psychiatrist, holds an academic position at Monash University through the Alfred Psychiatry Research Centre, and is the medical director of Malvern Private Hospital, the first addiction hospital in Australia. He is a member of the Australasian Professional Society on Alcohol and other Drugs (APSAD). Clinically, Eli is interested in the deep connections between trauma and addiction and works within a neuro-psychoanalytic framework. Eli has overseen the development of a clinical program for addictions focused on trauma, particularly developmental trauma. This has led to an interest in medication-assisted trauma therapy. Eli worked for many years researching neurodegenerative diseases and was the principle investigator on numerous trials for novel therapeutics. He is now involved in addiction research involving the retraining of neural pathways underlying incentive salience in meth addiction. Through involvement with Monash University, Eli overseas the addiction rotation for medical students.

• Vince Polito

  Senior Research Fellow in the Department of Cognitive Science at Macquarie University in Sydney

  Vince Polito

  Senior Research Fellow in the Department of Cognitive Science at Macquarie University in Sydney

  Vince Polito is a Senior Research Fellow in the Department of Cognitive Science at Macquarie University in Sydney, Australia and a former Associate Investigator of the Australian Research Council
  Centre of Excellence in Cognition and its Disorders. His research investigates cognitive and neurological changes in altered states of consciousness. He has investigated attentional capacities in
  meditation, psychiatric symptoms of disturbed control, states of flow in expertise, hypnotic suggestions, and body representation alterations in virtual reality. He is particularly interested in how
  beliefs and expectations shape psychedelic experiences and conducted one of the first systematic observational studies of the effects of microdosing in healthy participants.

• Dr Simon Longstaff AO

  Executive Director of The Ethics Centre

  Dr Simon Longstaff AO

  Executive Director of The Ethics Centre

  Dr Simon Longstaff commenced his work as the first Executive Director of The Ethics Centre in 1991. He undertook postgraduate studies in Philosophy as a Member of Magdalene College, Cambridge.

  Simon is a Fellow of CPA Australia and in June 2016, was appointed an Honorary Professor at the Australian National University – based at the National Centre for Indigenous Studies. Formerly serving as the inaugural President of The Australian Association for Professional & Applied Ethics, Simon serves on a number of boards and committees across a broad spectrum of activities. He was formerly a Fellow of the World Economic Forum.

  Simon’s distinguished career includes being named as one of AFR Boss’ True Leaders for the 21st century. In 2013 Dr Longstaff was made an officer of the Order of Australia (AO) for “distinguished service to the community through the promotion of ethical standards in governance and business, to improving corporate responsibility, and to philosophy.”

• Tania de Jong AM

  Founder Creative Universe, Creativity Australia, Creative Innovation Global and Mind Medicine Australia

  Tania de Jong AM

  Founder Creative Universe, Creativity Australia, Creative Innovation Global and Mind Medicine Australia

  Tania is an acclaimed Australian soprano and one of Australia’s most successful female entrepreneurs and innovators having developed 5 businesses and 3 charities over the past 3 decades.
  She is the Founder of Creative Universe, Creativity Australia, Mind Medicine Australia, Creative Innovation Global, Dimension5 co-working hub, MTA Entertainment & Events, Pot-Pourri and The Song Room.

  Tania presents keynote speeches and performs around the world. She has released 10 albums. She works across the public, private, creative and community sectors. Tania’s TED Talk How Singing Together Changes The Brain has sparked international interest.

  She was appointed a Member of the Order of Australia in June 2008. In 2018 Tania was named in the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs in Australia.

  Tania’s mission is to change the world, one voice at a time!

• Peter Hunt AM

  Investment Banker & engaged Philanthropist; Founder Women's Community Shelters and Mind Medicine Australia

  Peter Hunt AM

  Investment Banker & engaged Philanthropist; Founder Women's Community Shelters and Mind Medicine Australia

  Peter is Chairman and one of the original Founders of Greenhill Australia, a leading Australian corporate advisory firm that is now part of the global Greenhill advisory group. He has been advising local and multi-national companies and governments in Australia for over 25 years.

  In the NFP sector, Peter is Chairman, Grameen Australia; Chairman, So They Can, and Director and Founder, Women’s Community Shelters. Peter is also a member of the Advisory Councils of Mission Australia and the Centre for Social Impact. Previous roles in the sector have included Chairman, AMP Foundation; Chairman, Australian String Quartet; Trustee, St Vincent’s Clinic Foundation; a Director, Odyssey House and a Director, St James Ethics Centre.

  Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.

View all speakers